Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression.

Farinello D, Wozińska M, Lenti E, Genovese L, Bianchessi S, Migliori E, Sacchetti N, di Lillo A, Bertilaccio MTS, de Lalla C, Valsecchi R, Gleave SB, Lligé D, Scielzo C, Mauri L, Ciampa MG, Scarfò L, Bernardi R, Lazarevic D, Gonzalez-Farre B, Bongiovanni L, Campo E, Cerutti A, Ponzoni M, Pattini L, Caligaris-Cappio F, Ghia P, Brendolan A.

Nat Commun. 2018 May 3;9(1):1787. doi: 10.1038/s41467-018-04150-7.

2.

Harnessing the CD1 restricted T cell response for leukemia adoptive immunotherapy.

Consonni M, de Lalla C, Bigi A, Dellabona P, Casorati G.

Cytokine Growth Factor Rev. 2017 Aug;36:117-123. doi: 10.1016/j.cytogfr.2017.06.007. Epub 2017 Jul 8. Review.

PMID:
28712863
3.

Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.

Gorini F, Azzimonti L, Delfanti G, Scarfò L, Scielzo C, Bertilaccio MT, Ranghetti P, Gulino A, Doglioni C, Di Napoli A, Capri M, Franceschi C, Caligaris-Cappio F, Ghia P, Bellone M, Dellabona P, Casorati G, de Lalla C.

Blood. 2017 Jun 29;129(26):3440-3451. doi: 10.1182/blood-2016-11-751065. Epub 2017 May 2.

PMID:
28465341
4.

Group 1 CD1-restricted T cells and the pathophysiological implications of self-lipid antigen recognition.

Dellabona P, Consonni M, de Lalla C, Casorati G.

Tissue Antigens. 2015 Dec;86(6):393-405. doi: 10.1111/tan.12689. Epub 2015 Oct 30. Review.

PMID:
26514448
5.

Targeting leukemia by CD1c-restricted T cells specific for a novel lipid antigen.

Lepore M, de Lalla C, Mori L, Dellabona P, De Libero G, Casorati G.

Oncoimmunology. 2014 Dec 3;4(3):e970463. eCollection 2015 Mar.

6.

A novel self-lipid antigen targets human T cells against CD1c(+) leukemias.

Lepore M, de Lalla C, Gundimeda SR, Gsellinger H, Consonni M, Garavaglia C, Sansano S, Piccolo F, Scelfo A, Häussinger D, Montagna D, Locatelli F, Bonini C, Bondanza A, Forcina A, Li Z, Ni G, Ciceri F, Jenö P, Xia C, Mori L, Dellabona P, Casorati G, De Libero G.

J Exp Med. 2014 Jun 30;211(7):1363-77. doi: 10.1084/jem.20140410. Epub 2014 Jun 16.

8.

Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+ and CD4- subset dynamics and correlates with remission state.

de Lalla C, Rinaldi A, Montagna D, Azzimonti L, Bernardo ME, Sangalli LM, Paganoni AM, Maccario R, Di Cesare-Merlone A, Zecca M, Locatelli F, Dellabona P, Casorati G.

J Immunol. 2011 Apr 1;186(7):4490-9. doi: 10.4049/jimmunol.1003748. Epub 2011 Feb 25.

9.

High-frequency and adaptive-like dynamics of human CD1 self-reactive T cells.

de Lalla C, Lepore M, Piccolo FM, Rinaldi A, Scelfo A, Garavaglia C, Mori L, De Libero G, Dellabona P, Casorati G.

Eur J Immunol. 2011 Mar;41(3):602-10. doi: 10.1002/eji.201041211. Epub 2011 Jan 18.

10.

On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies.

Dellabona P, Casorati G, de Lalla C, Montagna D, Locatelli F.

Clin Immunol. 2011 Aug;140(2):152-9. doi: 10.1016/j.clim.2010.11.015. Epub 2010 Dec 24. Review.

PMID:
21185785
11.

Expression of functional GPR35 in human iNKT cells.

Fallarini S, Magliulo L, Paoletti T, de Lalla C, Lombardi G.

Biochem Biophys Res Commun. 2010 Jul 30;398(3):420-5. doi: 10.1016/j.bbrc.2010.06.091. Epub 2010 Jun 25.

PMID:
20599711
12.

Dicer-dependent microRNA pathway controls invariant NKT cell development.

Fedeli M, Napolitano A, Wong MP, Marcais A, de Lalla C, Colucci F, Merkenschlager M, Dellabona P, Casorati G.

J Immunol. 2009 Aug 15;183(4):2506-12. doi: 10.4049/jimmunol.0901361. Epub 2009 Jul 22.

13.

Innate-like effector differentiation of human invariant NKT cells driven by IL-7.

de Lalla C, Festuccia N, Albrecht I, Chang HD, Andolfi G, Benninghoff U, Bombelli F, Borsellino G, Aiuti A, Radbruch A, Dellabona P, Casorati G.

J Immunol. 2008 Apr 1;180(7):4415-24.

14.

CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells.

Thedrez A, de Lalla C, Allain S, Zaccagnino L, Sidobre S, Garavaglia C, Borsellino G, Dellabona P, Bonneville M, Scotet E, Casorati G.

Blood. 2007 Jul 1;110(1):251-8. Epub 2007 Mar 15.

PMID:
17363727
15.

Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis.

de Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A, Nuti S, Colombo M, Callea F, Porcelli SA, Panina-Bordignon P, Abrignani S, Casorati G, Dellabona P.

J Immunol. 2004 Jul 15;173(2):1417-25.

16.

Innate immune responses support adaptive immunity: NKT cells induce B cell activation.

Galli G, Nuti S, Tavarini S, Galli-Stampino L, De Lalla C, Casorati G, Dellabona P, Abrignani S.

Vaccine. 2003 Jun 1;21 Suppl 2:S48-54. Review.

PMID:
12763683
17.

CD1d-restricted help to B cells by human invariant natural killer T lymphocytes.

Galli G, Nuti S, Tavarini S, Galli-Stampino L, De Lalla C, Casorati G, Dellabona P, Abrignani S.

J Exp Med. 2003 Apr 21;197(8):1051-7. Epub 2003 Apr 14.

18.

Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2.

Turatti F, Mezzanzanica D, Nardini E, Luison E, Maffioli L, Bambardieri E, de Lalla C, Canevari S, Figini M.

Cancer Immunol Immunother. 2001 Feb;49(12):679-86.

PMID:
11258794
19.

Neonatal invariant Valpha24+ NKT lymphocytes are activated memory cells.

D'Andrea A, Goux D, De Lalla C, Koezuka Y, Montagna D, Moretta A, Dellabona P, Casorati G, Abrignani S.

Eur J Immunol. 2000 Jun;30(6):1544-50.

20.

Cutting edge: identification of novel T cell epitopes in Lol p5a by computational prediction.

de Lalla C, Sturniolo T, Abbruzzese L, Hammer J, Sidoli A, Sinigaglia F, Panina-Bordignon P.

J Immunol. 1999 Aug 15;163(4):1725-9.

21.

Biogenesis and function of IgM: the role of the conserved mu-chain tailpiece glycans.

de Lalla C, Fagioli C, Cessi FS, Smilovich D, Sitia R.

Mol Immunol. 1998 Sep;35(13):837-45.

PMID:
9839552
22.

Production of a soluble and functional recombinant streptavidin in Escherichia coli.

Gallizia A, de Lalla C, Nardone E, Santambrogio P, Brandazza A, Sidoli A, Arosio P.

Protein Expr Purif. 1998 Nov;14(2):192-6.

PMID:
9790881
23.

Differential expression of Galalpha1,3Gal epitope in polymeric and monomeric IgM secreted by mouse myeloma cells deficient in alpha2, 6-sialyltransferase.

Smilovich D, Malagolini N, Fagioli C, de Lalla C, Sitia R, Serafini-Cessi F.

Glycobiology. 1998 Aug;8(8):841-8.

PMID:
9637816
24.

Human recombinant antibody fragments specific for a rye-grass pollen allergen: characterization and potential applications.

de Lalla C, Tamborini E, Longhi R, Tresoldi E, Manoni M, Siccardi AG, Arosio P, Sidoli A.

Mol Immunol. 1996 Sep;33(13):1049-58.

PMID:
9010244
25.

Production, purification and characterization of an anti-(carcinoembryonic antigen) recombinant single-chain Fv antibody fragment.

Pérez L, Vázquez JE, Ayala M, Siccardi AG, Tresoldi E, de Lalla C, Gavilondo JV, Sidoli A.

Biotechnol Appl Biochem. 1996 Aug;24(1):79-82.

PMID:
8756397
26.

Lol pII allergen. Production and characterization of the recombinant protein and human antibody fragments.

Sidoli A, De Lalla C, Tamborini E, Brandazza A, Arosio P.

Adv Exp Med Biol. 1996;409:255-60. No abstract available.

PMID:
9095251
27.

Recombinant allergen Lol p II: expression, purification and characterization.

Tamborini E, Brandazza A, De Lalla C, Musco G, Siccardi AG, Arosio P, Sidoli A.

Mol Immunol. 1995 May;32(7):505-13.

PMID:
7783753
28.

Calmodulin as a versatile tag for antibody fragments.

Neri D, de Lalla C, Petrul H, Neri P, Winter G.

Biotechnology (N Y). 1995 Apr;13(4):373-7.

PMID:
9634779
29.

Cloning, expression, and immunological characterization of recombinant Lolium perenne allergen Lol p II.

Sidoli A, Tamborini E, Giuntini I, Levi S, Volonté G, Paini C, De Lalla C, Siccardi AG, Baralle FE, Galliani S, et al.

J Biol Chem. 1993 Oct 15;268(29):21819-25.

30.

Properties of a human monoclonal antibody specific for the NS4 region of hepatitis C virus.

de Lalla C, Cerino A, Rosa C, Griva S, Bonelli F, Mondelli MU.

J Hepatol. 1993 Jun;18(2):163-7.

PMID:
7691925
31.

Production and characterization of a human monoclonal antibody to the hepatitis C virus NS4 region.

Mondelli MU, Cerino A, Bellotti V, de Lalla C, Rosa C, Bonelli F, Habets W.

Year Immunol. 1993;7:220-6. No abstract available.

PMID:
8396822
32.

RIECA: an innovative immuno enzymatic competition assay for apolipoproteins AI and B determination.

Galliani S, Tosi C, Guintini I, Mariani C, de Lalla C, Da Ros B, Rossi P, Baralle FE, Sidoli A.

Ann Biol Clin (Paris). 1990;48(6):398-402.

PMID:
2121074
33.

Structure and properties of enzyme graft copolymers: Temperature effects on HRP immobilization mechanism.

D'Angiuro L, de Lalla C, Cremonesi P.

Biotechnol Bioeng. 1985 Nov;27(11):1548-53.

PMID:
18553607

Supplemental Content

Loading ...
Support Center